Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Biofrontera (BFRIW) EBT (2020 - 2025)

Historic EBT for Biofrontera (BFRIW) over the last 6 years, with Q3 2025 value amounting to -$6.6 million.

  • Biofrontera's EBT fell 1724.32% to -$6.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$17.5 million, marking a year-over-year decrease of 3689.84%. This contributed to the annual value of -$17.7 million for FY2024, which is 1183.08% up from last year.
  • According to the latest figures from Q3 2025, Biofrontera's EBT is -$6.6 million, which was down 1724.32% from -$5.3 million recorded in Q2 2025.
  • Biofrontera's EBT's 5-year high stood at $5.6 million during Q1 2022, with a 5-year trough of -$16.0 million in Q3 2021.
  • For the 5-year period, Biofrontera's EBT averaged around -$4.9 million, with its median value being -$4.2 million (2025).
  • Its EBT has fluctuated over the past 5 years, first surged by 25825.08% in 2022, then tumbled by 213755.27% in 2025.
  • Biofrontera's EBT (Quarter) stood at -$14.5 million in 2021, then skyrocketed by 80.8% to -$2.8 million in 2022, then skyrocketed by 226.44% to $3.5 million in 2023, then plummeted by 139.74% to -$1.4 million in 2024, then plummeted by 374.84% to -$6.6 million in 2025.
  • Its EBT stands at -$6.6 million for Q3 2025, versus -$5.3 million for Q2 2025 and -$4.2 million for Q1 2025.